The first domestic targeted il-36r monoclonal antibody was administered to the first subject in New Zealand
According to the official account of WeChat, Shanghai, China's Limited by Share Ltd has announced that the HB0034 project, the first recombinant IL-36R monoclonal antibody against human IL-36R, has been completed in New Zealand. The phase ia clinical study conducted in New Zealand aims to evaluate the safety, tolerance, immunogenicity and pharmacokinetics of hb0034 in healthy subjects. Huaaotai biology is a subsidiary of Huahai pharmaceutical, a listed company.
This text is a result of machine translation.
Related companies：
Briefing Feb 23, 2023 10:59 AM
· Technology
Power Device Company Maplesemi Completes Series A+ Financing Round
Briefing Feb 23, 2023 10:53 AM
· Technology
Acoustic Technology Company Audfly Completes Series B Financing Round
In-depth
Briefing Feb 23, 2023 10:45 AM
· Technology
Wicue Raised CNY 200 Mn in Series C+ Financing Round
Briefing Feb 23, 2023 10:36 AM
· Technology
Intelligent Industrial Drone and UAV Systems Developer I-KINGTEC Closed A Series C+ Financing Round
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Nov 10, 2022 02:39 PM
Nov 08, 2022 08:32 AM
Technology
Only 150,000 Units, Apple Vision Pro Orders Fall Short of Expectations
According to South Korean media reports, sources say that Apple has significantly lowered its sales target for its Mixed Reality (MR) headset, with initial orders coming in at just 150,000 units, well below the market's previous expectation of 1 million units.
Yesterday 09:39 AM
Briefing Aug 26, 2021 06:31 PM
· Healthcare
Huahai pharmaceutical: the net profit in the first half of the year was 516 million yuan, a year-on-year decrease of 10.84%
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth
Consumer Staples, Consumer Discretionary, Industrials · Analysis
TOPS in Shanghai: The New Trends in the Pet Industry's Overseas Expansion
May 12, 2023 01:33 PM